These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 4953646)

  • 1. Massive estrogen therapy: phase I study of hexestrol (NSC-9894).
    Weeth JB; Segaloff A
    Cancer Chemother Rep; 1965 Oct; 48():53-6. PubMed ID: 4953646
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytosine arabinoside (NSC-63878)--clinical brochure.
    Livingston RB; Carter SK
    Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
    [No Abstract]   [Full Text] [Related]  

  • 3. Toxicity and physiologic disposition of 2-amino-4',4"-bis(5-methyl-2-imidazolin-2-yl)terephthalanilide (NSC-66761).
    Philips FS; Sternberg SS; Cronin AP; Vidal PM
    Cancer Chemother Rep; 1966; 50(1):9-23. PubMed ID: 4956044
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical toxicologic evaluation of tetrahydrouridine (NSC-112907) in beagle dogs and rhesus monkeys.
    Goldenthal EI; Cookson KM; Geil RG; Wazeter FX
    Cancer Chemother Rep 3; 1974 Sep; 5(1):15-6. PubMed ID: 4213302
    [No Abstract]   [Full Text] [Related]  

  • 5. Preclinical toxicologic study of procarbazine (NSC-77213).
    Henry MC; Marlow M
    Cancer Chemother Rep 3; 1973 Jan; 4(1):97-102. PubMed ID: 4634121
    [No Abstract]   [Full Text] [Related]  

  • 6. Dibromodulcitol (NSC-104800)--clinical brochure.
    Carter SK
    Cancer Chemother Rep 3; 1968 Dec; 1(1):165-77. PubMed ID: 4989813
    [No Abstract]   [Full Text] [Related]  

  • 7. [Absorption, distribution and excretion of (carboxy-14C)bisbromoacetyl hexestrol].
    Ling YH; Hua Z; Sun SY; Liang YY
    Zhongguo Yao Li Xue Bao; 1984 Jun; 5(2):109-11. PubMed ID: 6087610
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxicity of N-diazoacetylglycine hydrazide (NSC-58404) in animals.
    Brambilla G; Mattioli F; Cavanna M; Parodi S; Baldini L
    Cancer Chemother Rep; 1969 Feb; 53(1):13-21. PubMed ID: 5772649
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical toxicology studies with ICRF-159 (NSC-129943)--a new antineoplastic drug.
    Gralla EJ; Coleman GL; Jonas AM
    Cancer Chemother Rep 3; 1974 Sep; 5(1):1-7. PubMed ID: 4213305
    [No Abstract]   [Full Text] [Related]  

  • 10. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.
    Freireich EJ; Gehan EA; Rall DP; Schmidt LH; Skipper HE
    Cancer Chemother Rep; 1966 May; 50(4):219-44. PubMed ID: 4957125
    [No Abstract]   [Full Text] [Related]  

  • 11. Formation of the depurinating N3adenine and N7guanine adducts by reaction of DNA with hexestrol-3',4'-quinone or enzyme-activated 3'-hydroxyhexestrol. Implications for a unifying mechanism of tumor initiation by natural and synthetic estrogens.
    Saeed M; Gunselman SJ; Higginbotham S; Rogan E; Cavalieri E
    Steroids; 2005 Jan; 70(1):37-45. PubMed ID: 15610895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical toxicology of alpha-2'-deoxythioguanosine (NSC-71851).
    Henry MC; DiDomenico E
    Cancer Chemother Rep 3; 1974 Sep; 5(1):9-14. PubMed ID: 4213304
    [No Abstract]   [Full Text] [Related]  

  • 13. Antitumor and hyperglycemic activity of streptozotocin (NSC-37917) and its cofactor, U-15,774.
    Evans JS; Gerritsen GC; Mann KM; Owen SP
    Cancer Chemother Rep; 1965 Oct; 48():1-6. PubMed ID: 4953644
    [No Abstract]   [Full Text] [Related]  

  • 14. [On some biological effects of the cytostatic agent verrucarin A].
    Rüsch ME; Stähelin H
    Arzneimittelforschung; 1965 Aug; 15(8):893-7. PubMed ID: 4955716
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic activation and formation of DNA adducts of hexestrol, a synthetic nonsteroidal carcinogenic estrogen.
    Jan ST; Devanesan PD; Stack DE; Ramanathan R; Byun J; Gross ML; Rogan EG; Cavalieri EL
    Chem Res Toxicol; 1998 May; 11(5):412-9. PubMed ID: 9585471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man.
    Homan ER
    Cancer Chemother Rep 3; 1972 May; 3(1):13-9. PubMed ID: 4626119
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II clinical study of hexestrol (NSC-9894).
    Mrazek R; Andrews NC; Bisel HF; Wilson WL; Hummel RP
    Cancer Chemother Rep; 1968 Dec; 52(7):751-3. PubMed ID: 5743712
    [No Abstract]   [Full Text] [Related]  

  • 18. Toxicology of environmental agents: a blend of applied and basic research.
    Dixon RL
    Environ Health Perspect; 1972 Oct; 2():103-16. PubMed ID: 4628852
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of 4-carbethoxy-5(3,3-dimethyl-1-triazeno)-2-phenylimidazole (NSC-166721) and 4-carbethoxy-5-(3,3-dimethyl-1-triazeno)-2-methylimidazole (NSC-166722) as potential antitumor agents.
    Heyes J; Catherall EJ; Cockburn A
    Cancer Chemother Rep; 1973; 57(3):263-8. PubMed ID: 4751253
    [No Abstract]   [Full Text] [Related]  

  • 20. Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology.
    Prieur DJ; Young DM; Davis RD; Cooney DA; Homan ER; Dixon RL; Guarino AM
    Cancer Chemother Rep 3; 1973 Jan; 4(1):1-39. PubMed ID: 4634117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.